WO2004062693A1 - 遺伝子治療用ベクター及び該遺伝子治療用ベクターを投与された哺乳動物中又は培養細胞中の目的タンパク質の定量方法 - Google Patents
遺伝子治療用ベクター及び該遺伝子治療用ベクターを投与された哺乳動物中又は培養細胞中の目的タンパク質の定量方法Info
- Publication number
- WO2004062693A1 WO2004062693A1 PCT/JP2003/016956 JP0316956W WO2004062693A1 WO 2004062693 A1 WO2004062693 A1 WO 2004062693A1 JP 0316956 W JP0316956 W JP 0316956W WO 2004062693 A1 WO2004062693 A1 WO 2004062693A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vector
- glucagon
- gene therapy
- target protein
- amino acid
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 84
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 77
- 239000013598 vector Substances 0.000 title claims abstract description 68
- 238000001415 gene therapy Methods 0.000 title claims abstract description 56
- 241000124008 Mammalia Species 0.000 title claims description 19
- 238000000034 method Methods 0.000 title claims description 19
- 210000004748 cultured cell Anatomy 0.000 title claims description 11
- 229960004666 glucagon Drugs 0.000 claims abstract description 70
- 108060003199 Glucagon Proteins 0.000 claims abstract description 67
- 102000051325 Glucagon Human genes 0.000 claims abstract description 65
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 57
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims abstract description 55
- 210000004369 blood Anatomy 0.000 claims abstract description 31
- 239000008280 blood Substances 0.000 claims abstract description 31
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 31
- 150000001413 amino acids Chemical class 0.000 claims abstract description 28
- 239000013604 expression vector Substances 0.000 claims abstract description 24
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 23
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 23
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 10
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 10
- 238000001727 in vivo Methods 0.000 claims abstract description 7
- 238000002372 labelling Methods 0.000 claims description 14
- 108020001507 fusion proteins Proteins 0.000 claims description 13
- 102000037865 fusion proteins Human genes 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 230000021164 cell adhesion Effects 0.000 claims 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 claims 1
- 239000004062 cytokinin Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 6
- 230000001766 physiological effect Effects 0.000 abstract description 3
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 18
- 238000010586 diagram Methods 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 108091026890 Coding region Proteins 0.000 description 13
- 208000009525 Myocarditis Diseases 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 108091092584 GDNA Proteins 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000013602 Cardiac Myosins Human genes 0.000 description 2
- 108010051609 Cardiac Myosins Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001417092 Macrouridae Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101100014660 Rattus norvegicus Gimap8 gene Proteins 0.000 description 1
- 101001076395 Rattus norvegicus Interleukin-13 Proteins 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 108010015046 cell aggregation factors Proteins 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000018090 giant cell myocarditis Diseases 0.000 description 1
- 102000052624 human CXCL8 Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
Definitions
- Gene therapy vector and method for quantifying target protein in mammals or cultured cells to which the gene therapy vector has been administered are provided.
- the present invention relates to a vector for gene therapy for producing a target protein in a living body, which can easily quantify the target protein produced in a living body or cultured cells.
- the blood concentration of the target protein can be established if measurement methods are established for that protein, such as ELISA. If not, the concentration cannot be measured. Therefore, an Atsey method for measuring the protein concentration using a labeled protein has been commercialized and sold. However, the sensitivity of this measurement is low, and there is no established method for measuring blood concentration in gene therapy (Ref.Treatment of Murine Lupus with cDNA encoding I FN—rR Fc, The Journal of Clinical Investigation, July 2000, volume 106, Number 2 p207-215) quantifies the affected protein without measuring the target protein and indirectly proves the expression of the target protein. This is thought to indicate the difficulty of measuring blood levels.
- An object of the present invention is to provide a gene therapy vector that can monitor the blood concentration of a target protein in gene therapy with high sensitivity and hardly cause unwanted physiological action or antigen-antibody reaction due to labeling. It is to provide.
- the inventors of the present invention found that a gene containing a target protein to be produced in the body by gene therapy and a nucleic acid encoding a fusion protein of the 19-29 amino acid peptide at the C-terminal side of glucagon were inserted into the vector.
- the concentration of the target protein in the blood can be measured with high sensitivity using the above-mentioned glucagon peptide as a label, and the expression of undesired physiological effects and the induction of an immune response caused by the labeled peptide can be achieved.
- the present invention has a structure in which a nucleic acid encoding a fusion protein of a C-terminal 19-129 amino acid peptide region of glucagon and a target protein region to be produced in the body is incorporated into a mammalian cell expression vector, It is intended to provide a gene therapy vector capable of producing the fusion protein in mammalian cells.
- the present invention also provides a method for gene therapy, comprising: administering an effective amount of the vector for gene therapy of the present invention to a mammal or a cultured mammalian cell in which expression of the target protein in vivo or in cells is desired. I do.
- the present invention provides the use of the above-described gene therapy vector of the present invention for the production of a gene therapy drug. Furthermore, the present invention provides an immunoassay for a glucagon C-terminal 19-29 amino acid peptide region in a test sample collected from a mammal or a cultured mammalian cell to which the gene therapy vector of the present invention has been administered. And a method for quantifying the target protein produced in vivo or in cultured mammalian cells by expression of the gene therapy vector.
- the present invention provides a method for labeling a target protein produced by expression of an externally administered expression vector in a mammal or a cultured mammalian cell, comprising a 19-29 amino acid peptide at the C-terminal side of glucagon. Provide the agent.
- the present invention relates to the fusion of a target protein produced by the expression of an externally administered expression vector in the body of a mammal or cultured mammalian cells with a glucagon C-terminal 19-29 amino acid peptide as a labeling agent
- a target protein produced by the expression of an externally administered expression vector in the body of a mammal or cultured mammalian cells with a glucagon C-terminal 19-29 amino acid peptide as a labeling agent
- the target peptide produced in the body or in cultured cells is labeled with 19-29 amino acid peptide on the C-terminal side of glucagon, and is produced in the body or in cultured cells.
- Methods for labeling proteins are provided.
- the present invention provides a labeling agent for a target protein produced by expression of an expression vector, which is administered externally in a mammal or cultured mammalian cells, of a 19-29 amino acid peptide at the C-terminal side of glucagon. Provide for use.
- the present invention provides, for the first time, a gene therapy vector capable of measuring the blood concentration of a target protein with high sensitivity without the labeled peptide having a physiological effect.
- the C-terminal side 19-29 of glucagon has no physiological action by itself and is well conserved in various mammals, so it does not substantially elicit an immune response, Quantification can be performed by immunoassay with high sensitivity using a commercially available immunoassay kit.
- FIG. 1 shows the nucleotide sequence of an inserted nucleic acid fragment inserted into the vector for gene therapy prepared in Example 1, together with the amino acid sequence encoded by the fragment.
- FIG. 2 is a diagram showing a continuation of FIG.
- FIG. 3 is a diagram showing a continuation of FIG.
- FIG. 4 is a gene map of pGAGGS, which is a mammalian expression vector used in Examples 1 to 5.
- FIG. 5 is a graph showing the relationship between the number of days after administration of a gene therapy vector and the blood concentration of a target protein measured by measuring a glucagon-derived labeled peptide in Example 1.
- FIG. 6 shows the concentration of the target protein in blood when gene therapy was performed using the vector of the present invention, the case where gene therapy was performed using the vector of the present invention, and the glucagon-derived protein measured in Example 1.
- FIG. 4 is a graph showing a change over time in blood glucose level when gene therapy is performed using a vector into which a nucleic acid encoding a target protein not fused with a labeled peptide is inserted.
- FIG. 7 is a diagram showing the nucleotide sequence of the inserted nucleic acid fragment inserted into the gene therapy vector prepared in Example 2, together with the amino acid sequence encoded by the fragment.
- FIG. 8 is a diagram showing a continuation of FIG.
- FIG. 9 is a diagram showing a continuation of FIG.
- FIG. 10 is a graph showing the relationship between the number of days after administration of a gene therapy vector and the blood concentration of a target protein measured by measuring a glucagon-derived labeled peptide in Example 2.
- FIG. 11 is a diagram showing the number of days of engraftment of rat transplanted hearts in Example 2 and Comparative Example 2.
- FIG. 12 is a diagram showing the nucleotide sequence of the inserted nucleic acid fragment inserted into the vector for gene therapy prepared in Example 3, together with the amino acid sequence encoded thereby.
- FIG. 13 is a diagram showing a continuation of FIG.
- FIG. 14 is a diagram showing a continuation of FIG. 13.
- FIG. 15 is a diagram showing the nucleotide sequence of the inserted nucleic acid fragment inserted into the vector for gene therapy prepared in Comparative Example 3, together with the amino acid sequence encoded thereby.
- FIG. 16 is a diagram showing a continuation of FIG.
- FIG. 17 is a diagram showing the relationship between the number of days after administration of the gene therapy vector and the blood concentration of the target protein measured by measuring the glucagon-derived labeled peptide in Example 3.
- FIG. 18 is a diagram showing an area ratio of a myocarditis lesion site in a rat in Example 3 and Comparative Example 3.
- FIG. 19 is a view showing the nucleotide sequence of the inserted nucleic acid fragment inserted into the vector for gene therapy prepared in Example 4 together with the amino acid sequence encoded by the nucleic acid fragment.
- FIG. 20 is a view illustrating a sequel to FIG.
- FIG. 21 is a diagram showing a continuation of FIG. 20.
- FIG. 22 is a graph showing the relationship between the number of days after administration of a gene therapy vector and the blood concentration of a target protein measured by measuring a glucagon-derived labeled peptide in Example 4.
- FIG. 23 is a diagram showing an area ratio of a myocarditis lesion site in a rat in Example 4 and Comparative Example 4.
- FIG. 24 is a diagram showing the nucleotide sequence of the inserted nucleic acid fragment inserted into the vector for gene therapy prepared in Example 5, together with the amino acid sequence encoded by the fragment.
- FIG. 25 shows the blood concentration of the target protein measured by measuring the glucagon-derived labeled peptide and the blood concentration of the target protein measured by measuring human interleukin 8 in Example 5.
- FIG. 3 is a diagram showing a correlation with a concentration.
- the 19-29 amino acid peptide J at the C-terminal side of glucagon which is expressed by fusion with the target protein by the vector of the present invention, is the total of the 19th to 29th amino acids counted from the C-terminus of glucagon.
- 11 means a peptide consisting of one amino acid. That is, this peptide is a peptide having the amino acid sequence shown in SEQ ID NO: 1 in the sequence listing. Since the “19-29 amino acid peptide j on the C-terminal side of glucagon is used as a label for the target protein, it may be referred to as“ glucagon-derived labeled peptide J ”for convenience.
- the vector of the present invention incorporates a nucleic acid encoding a fusion protein of a glucagon-derived labeled peptide region and a target protein region.
- Expression vectors for mammalian cells used in the present invention are well known in the field of gene therapy, and are not limited as long as they are expression vectors for mammalian cells.
- the feature of the present invention lies in that a glucagon-derived labeled peptide region as a label of a target protein is expressed by fusing it with a target protein, and the expression vector for mammalian cells is not limited at all. Any known mammalian cell expression vector used in the field of therapy can be used. Although a plasmid vector or a virus vector may be used, a plasmid vector is preferred from the viewpoint of safety.
- Various expression vectors for mammalian cells are well known and commercially available, and these well-known or commercially available vectors can be preferably used.
- pCAGGS Efficient se lect ion on for high express express on transfactans with a nove l eukaryotic vector, Gene 1991 Dec. 15, 108 (2) p193-P199. Is shown in Fig. 4 and its nucleotide sequence is shown in SEQ ID No. 3 in the sequence listing.)
- the forces that can be created are not limited to these.
- the target protein to be produced in the body by gene therapy is not limited at all, and includes various cytokins such as interferon, interleukin and GTLA4, growth factors, hormones such as insulin and cell adhesion factors, and the like. These receptors can be exemplified.
- any antigen protein can be produced in the body to produce a gene vaccine.
- the target protein itself may be a fusion protein.
- the constant region (FG) of an immunoglobulin, preferably IgG, particularly IgG1 is fused to one end of a desired site where binding to the FG receptor is required to enhance the binding to the FG receptor. Tampa (See Examples 1 to 4 below).
- nucleotide sequence of the nucleic acid encoding the IgG FG region is well known.
- the nucleotide sequence of the nucleic acid encoding the human IgG FG region is described, for example, in GenBank Accession No. BG020823.
- the nucleotide sequence of the nucleic acid encoding the IgG FG region of the rat is shown in FIGS. 1 to 3 of the present application.
- the vector of the present invention can be obtained by inserting a nucleic acid encoding a fusion protein of a target protein and the above-mentioned labeled peptide into a cloning site of an expression vector for mammalian cells.
- the labeled peptide is fused to one end of the target protein, particularly to the C-terminus.
- Gene therapy can be performed by administering the gene therapy vector of the present invention to a mammal.
- the administration route is preferably parenteral administration such as intravenous injection or intramuscular injection.
- the amount can be appropriately determined according to the properties of the target protein, the type and degree of the disease to be treated, etc.
- a solution obtained by dissolving a gene therapy vector in Ringer's solution can be used as an injection, and an injection additive well known in the field of pharmaceutical preparations.
- the vector for gene therapy of the present invention can also be administered to mammalian cells cultured in vitro.
- a gene therapy in which cells such as medulla cells are taken out of the body and cultured, a gene vector is administered to the cultured cells, and the cells that have acquired the target protein producing ability are returned to the patient again.
- the vector for administration can also be administered to such cultured mammalian cells, or can be administered to mammalian cells cultured in experiments such as in vitro studies on the therapeutic effect of the gene therapy vector. .
- a fusion protein of the target protein and a glucagon-derived labeled peptide is produced by a vector introduced into the body.
- a vector for gene therapy to mammalian cells cultured in vitro
- fusion of the target protein with a glucagon-derived labeled peptide in the cultured cells is performed. Protein is produced. Since the target protein is fused with the labeled peptide, the concentration of the target protein can be measured by measuring the concentration of the glucagon-derived labeled peptide.
- kits for immunoassay of a glucagon-derived labeled peptide used in the present invention including an antibody obtained using a glucagon-derived labeled peptide as an antigen
- Glucagon RIA manufactured by Daiichi Radioisotope Research Institute. Kit, etc.
- the test sample for quantifying the labeled peptide derived from glucagon is various body fluids or tissues from the individual to which the vector for gene therapy of the present invention has been administered, or a dilution thereof, and is preferably whole blood, C) A blood sample such as serum or plasma or a dilution thereof, or a homogenate of cultured cells ⁇ culture supernatant when administering a gene therapy vector to mammalian cells cultured in vitro. .
- PGR was performed using 5'-gagaat tcatttaaatgagagcggccgccgtgcccagaaactgtg-3 'and o-tcaaccactgcacaaaatcttgg gctttacccggagagtgggagagact-3' as a primer, and the PGR product was further diluted 300 times.
- the obtained product was used as a ⁇ , and PGR was performed using 5'-gagaattcatttaaatgagagcg gccgccgtgcccagaaactgtg-3 'and 5'-gagagagagaattctcaggtattcatcaaccactgcacaa aatcttgggc-3' as a primer. It was integrated into the pGAGGS cloning site. As a result, pGAGGS-lgG-glu19-29 containing the Swal and Notl restriction enzyme sites (a glucagon-derived labeled peptide is located downstream of the FG region encoding immunoglobulin G1 (lgG1)). A nucleic acid fragment to which the region coding for was inserted was inserted into the EGOR I site of pGAGGS).
- PCR was performed using 5'-gagaattcatttaaatga ttctgctggtggtcctgatg-3 'and 5'-gcagcatcgcggccgcttcttctctgtcatcatggagaaa-3' as primers, and the PGR product was previously prepared. It was incorporated into pGAGG S-IgG-glu19-29 using Swal and NotI.
- the vector of the present invention in which the DNA fragment having the nucleotide sequence shown in SEQ ID NO: 2 (including the restriction enzyme site) was inserted into the EGO RI site of the above-described mammalian cell expression vector pCAGGS, Fabricated (Example 1).
- SEQ ID NO: 2 is shown in FIGS. 1 to 3 together with other information.
- the inserted nucleic acid fragment has an EGORI site at both ends, and a fusion protein of an interferon r receptor (IFR) protein and an Fc region of immunoglobulin G1 (IgGI). co downstream one de region is that region which co one de glucagon-derived labeled base peptide is bound (I MF r R- 1 gG- glucagon 29).
- a plasmid vector containing no glucagon-derived labeled peptide (Comparative Example 1) and a plasmid vector of the present invention containing a glucagon-derived labeled peptide (Example 1) prepared as described above (Example 1) were each treated with 7 rat tails.
- Gene injection was performed by rapid intravenous injection from a vein.
- the composition of the injection solution was such that 800 g of the plasmid was dissolved in 20 ml of Ringer's solution per animal. After injection, blood is collected with time, blood is collected, and the plasma of 1-10j «1 is diluted 100- to 1000-fold.
- RIA was carried out specifically as follows.
- Figure 5 shows the measurement results of blood concentration.
- the results were as good as m, and were measurable in all cases.
- gene therapy using a plasmid doctor containing no glucagon peptide (Comparative Example 1), similar tests showed lower sensitivity.
- Figure 6 shows the blood glucose levels 4, 8 and 12 hours after the intravenous injection of plasmid and the protein blood concentration values examined by the RIA measurement method as described above.
- Example 1 the blood concentration was 2 815 ⁇ 2318 ng / m after 4 hours, 6061 ⁇ 2789 ng / m after 8 hours, and 5752 ⁇ 2270 ng / ml after 12 hours, and the maximum blood concentration was 8 to 12 hours.
- blood glucose was 89.3 ⁇ 15.1 mg / dl (Example 1) vs 81.8 ⁇ 7.5 mg / dl (Comparative Example 1), and after 12 hours 63.5 ⁇ 5.7 tng / dl (Example 1) vs 71.4 There was no difference from ⁇ 6.9 mg / dl (Comparative Example 1).
- PGAGGS- IgG was prepared by the method described in example 1 - c thereby incorporating with Swal and not I to Glu19-29, nucleotide sequences (restriction sites also including Umate shown in FIG off to 9 and SEQ ID nO: 4
- the above-mentioned mammalian cell is a rat GTLA4-IgGlucagon 19 ⁇ 29 (a nucleic acid fragment having a rat IgG Fc coding region downstream of a rat CTLA4 coding region and a glucagon-derived labeled peptide coding region downstream thereof).
- the recombinant vector was administered to the rat after heart transplantation in the same manner as in Example 1, and the blood concentration was measured. The number of days the transplanted heart survived was also examined.
- LA4-lgG- glucagon 19 - 29 protein remained as shown in FIG. 7.
- Glucagon was unmeasurable before dilution at 100-fold dilution, but increased sharply on the first day, showed a protein concentration exceeding 5000 ng / ml, and then decreased gradually. Slaughtered 105 Until the day, the protein concentration exceeded 1000 ng / ml.
- FIG. 11 in Example 2, one out of ten animals was rejected on the 14th day, but the remaining nine animals survived until the 105th day when evaluated.
- CTLA4 does not contain PGAGGS - In SP-lgG- the group treated with glutaric exaggeration 19 _ 29 (Comparative Example 2), the five day 1 out of 5 mice in one animal is 6 days, 3 out of 7 days Rejected in eyes. This is significantly show the effectiveness of pGAGGS-GTLA4-lgG- glucagon 19 _ 29 treatment.
- 13- IgG- glucagon 19 - 29 protein has good sea urchin transition in Figure 1 7. That is, on day 1, the protein concentration exceeds 2000 ng / ml, After that, it gradually decreased, but showed a protein concentration of about 8 ng / ml until 16 days after sacrifice for evaluation. Further, as shown in FIG. 18, a group to which p GAGGS-IL13-lgG-glucagon 19-29 (a vector into which IL13-IgG-glucagon 19-29 was inserted -pGAGGS), which was the vector for gene therapy of the present invention, was administered.
- the rat IgG FG coding region, and a nucleic acid fragment to which a glucagon-derived labeled peptide coding region was bound downstream thereof were inserted into the EGO RI site of pGAGGS, an expression vector for mammalian cells, as described above.
- 1RA-IgG in rat cells - recombinant vectors expressing glucagon 19 '29 was fabricated (example 4).
- IgG- glucagon 19 _ 29 protein remained as shown in Figure 22. In other words, the protein concentration exceeded 2000 ng / ml on the first day, and then gradually decreased, but remained around 20 ng / ml until 16 days after sacrifice for evaluation. Also, as shown in Figure 23, Compared to Example 4 Comparative Example 4 significantly reduced the area of myocarditis lesion, pGAGG S- I L1 RA- 1 gG- glucagon 19 - 29 efficacy of the treatment it was shown.
- PGR was performed using 5'-gagaattGatttaaatgacttccaagctg gccgtggct-3 'and 5'-gcagcatcgcggccgctgaattctcagccctcttcaaaa-3' as a plasmid, and the PGR product was previously prepared, pGAGGS-gl. 9-29 was incorporated using Swal and Notl.
- the human 8 having the nucleotide sequence shown in Figure 24 and SEQ ID NO: 8 - mammals glucanotransferase Gon 19 _ 29 was the inserted into the EGO RI site of cell expression vector PG A6GS, recombinant vectors expressing 8- glucagon 19, 29 in the rat cells was prepared (example 5).
- Recombinant vectors were administered to rats in the same manner as in Example 1, blood was collected one day later, and the blood concentration was measured. The concentration of human-8 in the same sample was also determined. Human IL-8 was quantified using the IL-8 EASIA kit manufactured by BI0SURSE (Nivel! Es, Belgium) according to the protocol.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004566302A JP3974619B2 (ja) | 2003-01-10 | 2003-12-26 | 遺伝子治療用ベクター及び該遺伝子治療用ベクターを投与された哺乳動物中又は培養細胞中の目的タンパク質の定量方法 |
AU2003292685A AU2003292685A1 (en) | 2003-01-10 | 2003-12-26 | Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene theraphy |
US10/541,626 US20060223767A1 (en) | 2003-01-10 | 2003-12-26 | Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene therapy |
EP03768321A EP1582223A4 (en) | 2003-01-10 | 2003-12-26 | VECTOR FOR GENE THERAPY AND METHOD FOR THE QUANTIFICATION OF A TARGET PROTEIN IN MAMMALIAN OR CULTURAL CELLS BY APPLYING THE VECTOR FOR GENE THERAPY |
CA002512676A CA2512676A1 (en) | 2003-01-10 | 2003-12-26 | Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene theraphy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-3967 | 2003-01-10 | ||
JP2003003967 | 2003-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004062693A1 true WO2004062693A1 (ja) | 2004-07-29 |
Family
ID=32708933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/016956 WO2004062693A1 (ja) | 2003-01-10 | 2003-12-26 | 遺伝子治療用ベクター及び該遺伝子治療用ベクターを投与された哺乳動物中又は培養細胞中の目的タンパク質の定量方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20060223767A1 (ja) |
EP (1) | EP1582223A4 (ja) |
JP (1) | JP3974619B2 (ja) |
CN (1) | CN100346834C (ja) |
AU (1) | AU2003292685A1 (ja) |
CA (1) | CA2512676A1 (ja) |
WO (1) | WO2004062693A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108623691B (zh) * | 2017-03-17 | 2020-05-15 | 北京比洋生物技术有限公司 | IgG样长效免疫融合蛋白及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2002387A (en) * | 1977-07-22 | 1979-02-21 | Takeda Chemical Industries Ltd | Glucagon fragment and derivatives thereof |
EP0009147A2 (en) * | 1978-08-30 | 1980-04-02 | Takeda Chemical Industries, Ltd. | A method for enzyme immunoassay of pancreatic glucagon and a peptide-enzyme conjugate usable for the method |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2602679B1 (fr) * | 1986-08-14 | 1989-02-24 | Inst Nat Sante Rech Med | Nouvelles compositions pharmaceutiques renfermant comme principe actif regulateur du mouvement des ions calcium un fragment du glucagon, et preparation d'un tel fragment |
US5486599A (en) * | 1989-03-29 | 1996-01-23 | The Board Of Trustees Of The Leland Stanford Junior University | Construction and use of synthetic constructs encoding syndecan |
CN1230595A (zh) * | 1998-04-02 | 1999-10-06 | 武汉大学 | 缺失调亡抑制基因病毒的构建及在肿瘤基因治疗中的应用 |
EP1591453A1 (en) * | 1999-05-17 | 2005-11-02 | ConjuChem Inc. | Modified peptides yy and conjugates thereof |
MXPA03005036A (es) * | 2000-12-07 | 2003-09-05 | Lilly Co Eli | Proteinas de fusion glp-1. |
-
2003
- 2003-12-26 CA CA002512676A patent/CA2512676A1/en not_active Abandoned
- 2003-12-26 JP JP2004566302A patent/JP3974619B2/ja not_active Expired - Fee Related
- 2003-12-26 CN CNB2003801101527A patent/CN100346834C/zh not_active Expired - Fee Related
- 2003-12-26 US US10/541,626 patent/US20060223767A1/en not_active Abandoned
- 2003-12-26 WO PCT/JP2003/016956 patent/WO2004062693A1/ja not_active Application Discontinuation
- 2003-12-26 EP EP03768321A patent/EP1582223A4/en not_active Withdrawn
- 2003-12-26 AU AU2003292685A patent/AU2003292685A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2002387A (en) * | 1977-07-22 | 1979-02-21 | Takeda Chemical Industries Ltd | Glucagon fragment and derivatives thereof |
EP0009147A2 (en) * | 1978-08-30 | 1980-04-02 | Takeda Chemical Industries, Ltd. | A method for enzyme immunoassay of pancreatic glucagon and a peptide-enzyme conjugate usable for the method |
Non-Patent Citations (1)
Title |
---|
NAYLOR L.H.: "Reporter gene technology: The future looks bright", BIOCHEMICAL PHARMACOLOGY, vol. 58, no. 5, 1 September 1999 (1999-09-01), pages 749 - 757, XP002902679 * |
Also Published As
Publication number | Publication date |
---|---|
CA2512676A1 (en) | 2004-07-29 |
CN100346834C (zh) | 2007-11-07 |
CN1758924A (zh) | 2006-04-12 |
JP3974619B2 (ja) | 2007-09-12 |
EP1582223A4 (en) | 2007-01-17 |
US20060223767A1 (en) | 2006-10-05 |
AU2003292685A1 (en) | 2004-08-10 |
JPWO2004062693A1 (ja) | 2006-05-18 |
EP1582223A1 (en) | 2005-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101997241B1 (ko) | 삼중특이성 결합 단백질 및 사용 방법 | |
JP6348146B2 (ja) | 赤血球結合療法 | |
US20190225702A1 (en) | Innate immune cell trispecific binding proteins and methods of use | |
KR20210029210A (ko) | 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법 | |
KR20150124955A (ko) | 사람 성장 호르몬 유사체를 사용한 소아 성장 호르몬 결핍증의 치료 방법 | |
SK2292002A3 (en) | Pharmaceutical composition comprising baff-r polypeptide | |
JP2009513608A (ja) | エフェクターリンパ球と標的細胞とを結合する融合タンパク質 | |
CN104271148A (zh) | 红细胞结合性治疗剂 | |
WO2010070047A1 (en) | Soluble polypeptides for use in treating autoimmune and inflammatory disorders | |
SK286331B6 (en) | The use of a BCMA polypeptides and antibodies for the preparation of a pharmaceutical composition for treating a tumour cell that expresses APRIL | |
PT1812476E (pt) | Anticorpos anti-il-22ra e parceiros de ligação e métodos de utilização no tratamento de inflamações | |
BRPI0707425A2 (pt) | construção de anticorpo de domìnio, molécula isolada de ácido nucleico, composição farmacêutica, e, métodos para detectar tnf-alfa humano em uma amostra, e para tratar um distúrbio | |
WO2022031884A2 (en) | Il2rg binding molecules and methods of use | |
JPH08508884A (ja) | マクロファージ炎症蛋白変種 | |
US20230272090A1 (en) | Il2rb binding molecules and methods of use | |
JP2001509372A (ja) | 血小板凝集に関与する細胞表面受容体であるヒトf11抗原 | |
US11351227B2 (en) | Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof | |
KR20210005683A (ko) | Cd123 및 cd3에 결합하는 이중특이적 항체의 투약 | |
US9186390B2 (en) | Methods and uses of TIE2 binding and/or activating agents | |
EP2843051A1 (en) | Anti-human cd69 antibody, and use thereof for medical purposes | |
WO2004062693A1 (ja) | 遺伝子治療用ベクター及び該遺伝子治療用ベクターを投与された哺乳動物中又は培養細胞中の目的タンパク質の定量方法 | |
US20070179094A1 (en) | Modulation of MDL-1 activity for treatment of inflammatory disease | |
WO2021053681A1 (en) | Il-2 chimeric proteins for immunosuppression | |
CN115137815A (zh) | 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案 | |
TWI668010B (zh) | 使用glp-1及抗il-21治療糖尿病 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2512676 Country of ref document: CA Ref document number: 2004566302 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006223767 Country of ref document: US Ref document number: 10541626 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003768321 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038B01527 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003768321 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10541626 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003768321 Country of ref document: EP |